Hallandale Pharmacy

Hallandale is one of the larger consumer-facing 503A compounders — the kind of patient-specific pharmacy that fills prescriptions routed through telehealth practices. It’s a 503A (state-regulated, patient-specific), not a 503B outsourcing facility.

Facility & accreditation

Hallandale operates as a 503A pharmacy (legal entity “Pharmcore, LLC” dba Hallandale Pharmacy, Fort Lauderdale, FL); it is not on the FDA 503B outsourcing-facility list ^[3]. We independently confirmed its PCAB accreditation in ACHC’s own directory — listed under Pharmcore / Hallandale Pharmacy, Fort Lauderdale, FL, PCAB Compounding Pharmacy ^[2]. The company says it has operated since 2003 from a ~60,000-sq-ft facility, working with thousands of practitioners and shipping nationwide ^[1].

What they compound

Explicitly on-audience: weight management with compounded semaglutide (2.5 and 5 mg/mL) and tirzepatide (10 and 15 mg/mL), a dedicated peptide-therapy line, hormone replacement, sexual wellness, dermatology, fertility, and IV therapy ^[1].

Regulatory record

On March 11, 2020 the FDA sent a warning letter to Pharmcore Inc. dba Hallandale Pharmacy, after inspecting its former site in Hallandale, Florida from July 2 to 13, 2018 ^[4]. FDA has since taken the letter off its website; the link is to the Internet Archive’s copy of the FDA page. The letter found products made without valid prescriptions for individual patients, and insanitary conditions in the sterile suite, including power to the clean areas switched off during cleaning, holes in the walls and in a safety cabinet, and media fills not run under worst-case conditions. The pharmacy had recalled its aseptically made products in August 2018 and moved sterile compounding to a new site in Fort Lauderdale. FDA issued a close-out letter on May 3, 2022, and its list of compounding actions records a later Form 483 for the pharmacy, issued June 13, 2025 ^[5].

Hallandale does not appear on the FDA 503B list ^[3].

The read

A “pure 503A telehealth-partner” option with solid credentials: PCAB-accredited (independently confirmed), explicit compounded GLP-1 and peptide lines, long operating history, national reach. Its 2020 warning letter, about the site it has since left, was closed out in 2022; the 2025 Form 483 is the more recent record. The 503A model means state-board oversight rather than FDA CGMP — the standard trade-off versus a 503B like Empower.

References

1. Hallandale Pharmacy — official site. (accessed 2026-07-01)
2. ACHC / PCAB accredited-organization directory (listed as Pharmcore / Hallandale Pharmacy, Fort Lauderdale, FL). (accessed 2026-07-01)
3. FDA — Registered Outsourcing Facilities (503B) list (Hallandale not listed → confirms 503A). (accessed 2026-07-01)
4. FDA — Warning letter to Pharmcore Inc. dba Hallandale Pharmacy, MARCS-CMS 605569, March 11, 2020 (Internet Archive copy of the FDA page). (accessed 2026-10-21)
5. FDA — Compounding: Inspections, Recalls, and other Actions (Pharmcore Inc. dba Hallandale Pharmacy entry). (accessed 2026-10-21)